Novo Nordisk Partners with Telehealth for Wegovy Promotion
May 23, 2025Stat + by Katie Palmer https://ro.co/ https://lifemd.com/ Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the relationship between major pharmaceutical companies like Novo Nordisk and telehealth providers. After previously battling telehealth companies offering compounded versions of their drugs, Novo Nordisk is now collaborating with specific telehealth platforms, including Ro and LifeMD. This partnership […]
Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis
submitted by /u/PlayfulReputation112 [link] [comments]
Massive Study Of 215,000+ Ozempic Users Reveal Incredible Benefits Beyond Weight Loss
Shutterstock Few drugs in history have gone from initial approval to being a household name faster than the various GLP-1 drugs, including Ozempic and Wegovy. Maybe this isn’t surprising because they are known to be very effective for something that millions of people struggle with everyday. Weight loss. Many people who are on Ozempic or […]
Is Ozempic ruining your teeth? What to know about impact on dental health
Despite their widely touted benefits — primarily weight loss and diabetes control, among others — GLP-1 medications have also been linked to some unwelcome side effects. In addition to the main complaints of gastrointestinal issues, some lesser-known side effects have emerged, including mood changes, hair loss and “Ozempic face.” Now, there are rumblings on social […]
The most bizarre side effects of GLP-1 weight loss drugs, from ‘Ozempic feet’ to cavities to a runny nose
“We are just starting to learn more about the systemic impact of these medications,” Dr. Shiara Ortiz-Pujols told The Post.
ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death
For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according to a study scheduled to be presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
GLP-1 prescriptions for weight loss are shooting up, despite obstacles
The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a new Fair Health report.
Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight
Plus, news about Advanz, Alvotech and GeNeuro: Veru’s obesity drug generally safe when added to Wegovy: In the Phase 2b QUALITY trial, patients who were given enobosarm, an oral androgen receptor modulator …
GLP-1 prescriptions for weight loss soar, despite obstacles
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, according to a new report.